Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431. https://doi.org/10.1056/NEJMoa054481

Article  CAS  PubMed  Google Scholar 

Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444. https://doi.org/10.1056/NEJMoa062655

Article  CAS  PubMed  Google Scholar 

Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD (2010) A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 117:2134–2140. https://doi.org/10.1016/j.ophtha.2010.02.032

Article  PubMed  Google Scholar 

Otsuji T, Nagai Y, Sho K et al (2013) Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). Clin Ophthalmol 7:1487–1490. https://doi.org/10.2147/OPTH.S46317

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eghøj MS, Sørensen TL (2012) Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 96:21–23. https://doi.org/10.1136/bjo.2011.203893

Article  PubMed  Google Scholar 

Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT (2009) Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 29:723–731. https://doi.org/10.1097/IAE.0b013e3181a2c1c3

Article  PubMed  PubMed Central  Google Scholar 

Fassnacht-Riederle H, Becker M, Graf N, Michels S (2014) Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol 252:1705–1709. https://doi.org/10.1007/s00417-014-2589-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heussen FM, Shao Q, Ouyang Y, Joussen AM, Müller B (2014) Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 252:909–915. https://doi.org/10.1007/s00417-013-2553-7

Article  CAS  PubMed  Google Scholar 

Amoaku WM, Chakravarthy U, Gale R et al (2015) Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond) 29:1397–1398. https://doi.org/10.1038/eye.2015.48

Article  CAS  PubMed  Google Scholar 

Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P (2016) Intravitreal aflibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy. Retina 36:770–777. https://doi.org/10.1097/IAE.0000000000000751

Article  CAS  PubMed  Google Scholar 

Atzeni F, Talotta R, Salaffi F et al (2013) Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 12:703–708. https://doi.org/10.1016/j.autrev.2012.10.021

Article  CAS  PubMed  Google Scholar 

De Groot AS, Scott DW (2007) Immunogenicity of protein therapeutics. Trends Immunol 28:482–490. https://doi.org/10.1016/j.it.2007.07.011

Article  CAS  PubMed  Google Scholar 

Fox EJ, Vartanian TK, Zamvil SS (2007) The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist 13:355–362. https://doi.org/10.1097/NRL.0b013e318148c08e

Article  PubMed  Google Scholar 

van Schouwenburg PA, Rispens T, Wolbink GJ (2013) Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 9:164–172. https://doi.org/10.1038/nrrheum.2013.4

Article  CAS  PubMed  Google Scholar 

Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ (2020) Immunogenicity of TNF-inhibitors. Front Immunol 11:312. https://doi.org/10.3389/fimmu.2020.00312

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heier JS, Boyer DS, Ciulla TA et al (2006) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 124:1532–1542. https://doi.org/10.1001/archopht.124.11.1532

Article  CAS  PubMed  Google Scholar 

Bressler NM, Kim T, Oh I, Russo P, Kim MY, Woo SJ (2023) Immunogenicity with ranibizumab biosimilar SB11 (Byooviz) and reference product Lucentis and association with efficacy, safety, and pharmacokinetics: a post hoc analysis of a phase 3 randomized clinical trial. JAMA Ophthalmol 141:117–127. https://doi.org/10.1001/jamaophthalmol.2022.5403

Article  PubMed  Google Scholar 

Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V (2005) Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726–733. https://doi.org/10.1167/iovs.04-0601

Article  PubMed  Google Scholar 

Yoon CK, Oh J, Bae K, Park UC, Yu KS, Yu HG (2022) Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: a phase 3 randomized clinical trial. PLoS One 17:e0275611. https://doi.org/10.1371/journal.pone.0275611

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen WY, Yu MJ, Barry CJ, Constable IJ, Rakoczy PE (1998) Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat. Br J Ophthalmol 82:1063–1071. https://doi.org/10.1136/bjo.82.9.1063

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu E, Palmer N, Tian Z et al (2008) Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One 3:e3794. https://doi.org/10.1371/journal.pone.0003794

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rusnati M, Presta M (2007) Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des 13:2025–2044. https://doi.org/10.2174/138161207781039689

Article  CAS  PubMed  Google Scholar 

Stein-Streilein J (2008) Immune regulation and the eye. Trends Immunol 29:548–554. https://doi.org/10.1016/j.it.2008.08.002

Article  CAS  PubMed  Google Scholar 

Niederkorn JY (2007) The induction of anterior chamber-associated immune deviation. Chem Immunol Allergy 92:27–35. https://doi.org/10.1159/000099251

Article  CAS  PubMed  Google Scholar 

Blana SA, Musshoff F, Hoeller T, Fimmers R, Madea B (2011) Variations in vitreous humor chemical values as a result of pre-analytical treatment. Forensic Sci Int 210:263–270. https://doi.org/10.1016/j.forsciint.2011.03.023

Article  CAS  PubMed  Google Scholar 

Laude A, Cackett PD, Vithana EN et al (2010) Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 29:19–29. https://doi.org/10.1016/j.preteyeres.2009.10.001

Article  PubMed  Google Scholar 

Cheung GCM, Lai TYY, Gomi F, Ruamviboonsuk P, Koh A, Lee WK (2017) Anti-VEGF therapy for neovascular AMD and polypoidal choroidal vasculopathy. Asia Pac J Ophthalmol (Phila) 6:527–534. https://doi.org/10.22608/APO.2017260

Article  CAS  PubMed  Google Scholar 

Abdullah SE, Perez-Soler R (2012) Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer 118:3455–3467. https://doi.org/10.1002/cncr.26540

Article  CAS  PubMed  Google Scholar 

Inai T, Mancuso M, Hashizume H et al (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35–52. https://doi.org/10.1016/S0002-9440(10)63273-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Campa C, Costagliola C, Incorvaia C et al (2010) Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm 2010:546826. https://doi.org/10.1155/2010/546826

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lorés-Motta L, Riaz M, Grunin M et al (2018) Association of genetic variants with response to anti- vascular endothelial growth factor therapy in age-related macular degeneration. JAMA Ophthalmol 136:875–884. https://doi.org/10.1001/jamaophthalmol.2018.2019

Article  PubMed  PubMed Central  Google Scholar